# Eric A. Klein

Source: https://onco.cc/people/eric-klein/  
OnCo record `eric-klein` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Urologist who led the CCGA study validating the Galleri methylation-based multi-cancer detection test.

## Summary

Eric Klein led the Circulating Cell-free Genome Atlas (CCGA) study that developed and clinically validated the Galleri cell-free DNA methylation test for detecting more than 50 cancer types and predicting tissue of origin, the basis for the PATHFINDER and NHS-Galleri trials. As a urologist he led the SELECT prevention trial and the development of the Oncotype DX prostate score.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: early-detection; mced; prostate
- Role: Emeritus Professor and Chairman, Glickman Urological and Kidney Institute, Cleveland Clinic; Distinguished Scientist, GRAIL
- Specialisms: Multi-cancer early detection; Prostate cancer; Genomic classifiers; Urologic oncology

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Klein%20EA%5BAuthor%5D%20multi-cancer%20early%20detection

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [DNA methylation profiling](https://onco.cc/technologies/methylation-profiling/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [Galleri](https://onco.cc/drugs/galleri/)
- institutions: [Cleveland Clinic Taussig Cancer Institute](https://onco.cc/institutions/cleveland-clinic/)
- trials: [NHS-Galleri](https://onco.cc/trials/nhs-galleri/), [PATHFINDER 2](https://onco.cc/trials/pathfinder-2/)
- key papers: [PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms](https://onco.cc/key-papers/paper-pathfinder-lancet-2023/)
- journals: [Annals of Oncology](https://onco.cc/journals/annals-of-oncology/)

---
JSON: https://onco.cc/api/v1/entities/eric-klein.json